American Century Companies Inc. Has $33.82 Million Position in Arcellx, Inc. $ACLX

American Century Companies Inc. lessened its holdings in Arcellx, Inc. (NASDAQ:ACLX) by 4.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 411,930 shares of the company’s stock after selling 19,536 shares during the period. American Century Companies Inc. owned 0.71% of Arcellx worth $33,820,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in ACLX. Xponance Inc. acquired a new position in shares of Arcellx in the third quarter valued at $221,000. US Bancorp DE lifted its stake in shares of Arcellx by 57.2% during the 3rd quarter. US Bancorp DE now owns 1,797 shares of the company’s stock worth $148,000 after buying an additional 654 shares during the last quarter. MAI Capital Management acquired a new stake in shares of Arcellx during the 3rd quarter worth about $26,000. TD Asset Management Inc boosted its holdings in shares of Arcellx by 124.9% during the 3rd quarter. TD Asset Management Inc now owns 232,708 shares of the company’s stock worth $19,105,000 after buying an additional 129,248 shares during the period. Finally, Monaco Asset Management SAM acquired a new position in Arcellx in the 3rd quarter valued at about $6,452,000. Institutional investors and hedge funds own 96.03% of the company’s stock.

Analyst Ratings Changes

ACLX has been the topic of several research analyst reports. Wolfe Research began coverage on shares of Arcellx in a report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Robert W. Baird reaffirmed a “neutral” rating and issued a $115.00 target price (up from $106.00) on shares of Arcellx in a research report on Monday, February 23rd. Rothschild & Co Redburn lowered Arcellx from a “buy” rating to a “neutral” rating and set a $82.00 target price on the stock. in a research note on Thursday, February 12th. Guggenheim cut Arcellx from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $120.00 to $115.00 in a report on Wednesday, February 25th. Finally, UBS Group downgraded Arcellx from a “buy” rating to a “neutral” rating and boosted their price target for the company from $100.00 to $115.00 in a research note on Tuesday, February 24th. One analyst has rated the stock with a Buy rating, seventeen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $111.87.

Arcellx Stock Down 0.0%

Shares of NASDAQ:ACLX opened at $114.33 on Friday. Arcellx, Inc. has a 12-month low of $47.86 and a 12-month high of $114.80. The company’s 50 day moving average price is $76.67 and its two-hundred day moving average price is $77.72. The firm has a market cap of $6.69 billion, a PE ratio of -28.09 and a beta of 0.23.

Arcellx (NASDAQ:ACLX) last released its quarterly earnings results on Thursday, February 26th. The company reported ($1.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.01). The company had revenue of $1.65 million during the quarter, compared to the consensus estimate of $13.40 million. Arcellx had a negative net margin of 1,027.26% and a negative return on equity of 55.42%. On average, research analysts expect that Arcellx, Inc. will post -1.58 EPS for the current year.

Insiders Place Their Bets

In other news, insider Christopher Heery sold 7,437 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $65.51, for a total transaction of $487,197.87. Following the sale, the insider directly owned 29,631 shares of the company’s stock, valued at approximately $1,941,126.81. This represents a 20.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Rami Elghandour sold 89,916 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $113.92, for a total value of $10,243,230.72. Following the completion of the transaction, the insider owned 276,051 shares in the company, valued at $31,447,729.92. The trade was a 24.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 109,366 shares of company stock worth $11,526,708. Corporate insiders own 8.35% of the company’s stock.

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.